New cholesterol-buster from Esperion now available in U.S.
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …